The number of long-term breast cancer survivors with a risk of late recurrence is increasing. Hormone-receptor-positive patients have greater risks of late recurrence.
| INTRODUCTION
Breast cancer is one of the most common diseases worldwide.
Approximately, 1.67 million new cases are diagnosed and 522 000 cancer-related deaths occur globally each year. 1 Twenty-five percent of cases relapse after initial treatment. More than half of all recurrences occur after 5 years of adjuvant endocrine therapy, especially in estrogen receptor (ER)-positive breast cancer. 2, 3 Ten, rather than 5, years of tamoxifen therapy reduced the late recurrence risk in ERpositive breast cancer. 4 An additional 5 years of letrozole after 5 years of tamoxifen improved disease-free survival (DFS) in ERpositive and/or progesterone receptor (PgR)-positive patients. 5 Accordingly, endocrine treatment for 10 years is recommended for most ER-positive breast cancer patients. 6 However, the absolute risk reduction of any recurrence by extended adjuvant tamoxifen is only 2.7%. 7 Moreover, adverse effects, such as pulmonary embolus,
| Statistical analysis
Differences in frequency distribution were compared using the chisquared test. Age and mean tumor size were tested using the MannWhitney test. Cumulative DFS was calculated using the KaplanMeier method and tested using the log-rank test. Univariate and multivariate analyses for factors related to late recurrence were tested using the Cox proportional hazard model. All statistical analyses were conducted using STATA SE 13 software (Stata Crop LP, college Station, TX). A P value < .05 was considered statistically significant. received endocrine therapy (P = .0003) ( Figure 1A ).
| RESULTS
Irrespective of menopausal status, women with late recurrence had a higher pathological lymph node category than those without (Table 3) . Age, tumor size, nuclear grade, LVI, proportion of patients receiving chemotherapy, proportion of patients receiving radiotherapy, and type of surgery were not significantly different between the 2 groups. In contrast, the proportion of patients receiving endocrine therapy was significantly higher in women without recurrence than in those with late recurrence (P = .048
for premenopausal patients and P = .001 for postmenopausal patients). For premenopausal women, multivariate analysis revealed that >4 involved lymph nodes were significant risk factors (HR 2.73; 95% CI, 1.38-5.41, P = .004) for late recurrence, whereas 1-3 positive nodes were not (HR 1.20; 95% CI, 0.63-2.27, P = .579) ( trial demonstrated that recurrence rates remained significantly lower on anastrozole than tamoxifen after treatment. An absolute reduction of recurrence of 4.3% at 10 years was reported for anastrozole compared with tamoxifen in hormone-receptor-positive patients. 8 The Breast International Group (BIG) 1-98 study showed significantly improved DFS for letrozole compared with tamoxifen at 8 years from the initial treatment (76.4% vs 72.0%). 9 Our results indicated that regimens with aromatase inhibitors are more effective than tamoxifen therapy alone in postmenopausal hormone-receptor-positive breast cancer.
Chemotherapy did not reduce the risk of late recurrence in our study. Polychemotherapy regimens including anthracycline reduce recurrence and mortality from breast cancer; however, most effects of adjuvant chemotherapy occurred within 5 years of the initial treatment. 10 The effect of adjuvant chemotherapy including cyclophosphamide, methotrexate, 5-fluorouracil (CMF) was only seen within 4 years after diagnosis. 11 Adjuvant chemotherapy improves DFS among patients with both node-positive and node-negative disease. However, the absolute 5-year gains for node-negative disease are smaller than those for node-positive disease. 10 In our study, the proportion of node-negative disease was higher than that of other studies, which may explain why chemotherapy did not reduce the risk of late recurrence.
In our study, >4 positive nodes were significant risk factors for early and late recurrence, while 1-3 positive nodes were marginal risk factors for early recurrence and did not affect late recurrence.
This trend continued beyond 5 years after surgery. 12 One to 3 positive nodes (N1) and >4 positive nodes (N2) were both significant risk factors for late recurrence. Moreover, patients with >4 positive nodes had a higher annual risk of recurrence during the 6-10 years after diagnosis than those with 1-3 positive nodes or negative nodes (7.6%, 3.5% and 2.2%, respectively). 13 Tumor size was not a significant predictor of late recurrence in our study, nor a predictive factor for recurrence in patients who did not receive adjuvant therapy for >20 years. 14 Yamashita et al 15 reported that a large tumor size was a predictor of late recurrence in ER-positive, human epidermal growth factor receptor (HER2)-negative premenopausal women, and postmenopausal women under 60 years of age. The proportion of large tumors (>2 cm in diameter) was higher than in our study (70.4% and 54.2%, respectively) and the number of patients with late recurrence was higher than in our study (149 and 83, respectively), which might account for the different results. On the other hand, tumor size was not predictive of late recurrence in a previous study although late recurrence was defined as recurrence after 10 years from the initial treatment. 16 Our results indicated that nuclear grade was a predictor of early recurrence (data not shown), but not of late recurrence. Sestak et al 17 reported that tumor grade was predictive of early but not late Further studies are needed to evaluate the biologic effect of these factors on early and late recurrence.
High nodal involvement correlated with late recurrence in hormone-receptor-positive breast cancer and extended endocrine therapy should be considered. Hormone-receptor-positive patients who received adjuvant endocrine therapy with tamoxifen alone might be candidates for extended endocrine therapy.
